Eckert & Ziegler Strahlen- und Medizintechnik AG
Eckert & Ziegler SE manufactures and sells isotope technology components worldwide. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of uveal melanomas; brain seed, HDR and brachytherapy; therapeutic and radiotherapy accessories… Read more
Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) - Net Assets
Latest net assets as of September 2025: €233.15 Million EUR
Based on the latest financial reports, Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) has net assets worth €233.15 Million EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€452.04 Million) and total liabilities (€218.89 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €233.15 Million |
| % of Total Assets | 51.58% |
| Annual Growth Rate | 8.67% |
| 5-Year Change | 51.23% |
| 10-Year Change | 115.17% |
| Growth Volatility | 7.24 |
Eckert & Ziegler Strahlen- und Medizintechnik AG - Net Assets Trend (2013–2024)
This chart illustrates how Eckert & Ziegler Strahlen- und Medizintechnik AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Eckert & Ziegler Strahlen- und Medizintechnik AG (2013–2024)
The table below shows the annual net assets of Eckert & Ziegler Strahlen- und Medizintechnik AG from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €225.21 Million | +0.50% |
| 2023-12-31 | €224.09 Million | +4.90% |
| 2022-12-31 | €213.63 Million | +10.96% |
| 2021-12-31 | €192.53 Million | +29.28% |
| 2020-12-31 | €148.92 Million | +6.80% |
| 2019-12-31 | €139.44 Million | +12.56% |
| 2018-12-31 | €123.88 Million | +5.41% |
| 2017-12-31 | €117.52 Million | +6.76% |
| 2016-12-31 | €110.08 Million | +5.17% |
| 2015-12-31 | €104.67 Million | +10.77% |
| 2014-12-31 | €94.49 Million | +4.68% |
| 2013-12-31 | €90.27 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Eckert & Ziegler Strahlen- und Medizintechnik AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 348.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €128.00 Million | 57.28% |
| Other Components | €95.45 Million | 42.72% |
| Total Equity | €223.45 Million | 100.00% |
Eckert & Ziegler Strahlen- und Medizintechnik AG Competitors by Market Cap
The table below lists competitors of Eckert & Ziegler Strahlen- und Medizintechnik AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Liquidity Services Inc
NASDAQ:LQDT
|
$610.07 Million |
|
Beijing Utour International Travel Service Co Ltd
SHE:002707
|
$610.74 Million |
|
Yijiahe Technology Co Ltd
SHG:603666
|
$610.85 Million |
|
Hubei Zhongyi Science Technology Co. Ltd.
SHE:301150
|
$610.94 Million |
|
Adrian Resources Ltd
PINK:ADLRF
|
$609.82 Million |
|
Southern Publishing&Media Co
SHG:601900
|
$609.77 Million |
|
ARIAKE JAPAN CO.LTD
F:5EF
|
$609.54 Million |
|
NioCorp Developments Ltd. Common Stock
NASDAQ:NB
|
$609.49 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Eckert & Ziegler Strahlen- und Medizintechnik AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 222,176,000 to 223,450,000, a change of 1,274,000 (0.6%).
- Net income of 33,276,000 contributed positively to equity growth.
- Dividend payments of 1,042,000 reduced retained earnings.
- Share repurchases of 746,000 reduced equity.
- Other factors decreased equity by 30,214,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €33.28 Million | +14.89% |
| Dividends Paid | €1.04 Million | -0.47% |
| Share Repurchases | €746.00K | -0.33% |
| Other Changes | €-30.21 Million | -13.52% |
| Total Change | €- | 0.57% |
Book Value vs Market Value Analysis
This analysis compares Eckert & Ziegler Strahlen- und Medizintechnik AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.35x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.73x to 1.35x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €5.31 | €14.51 | x |
| 2018-12-31 | €6.06 | €14.51 | x |
| 2019-12-31 | €6.71 | €14.51 | x |
| 2020-12-31 | €7.18 | €14.51 | x |
| 2021-12-31 | €9.03 | €14.51 | x |
| 2022-12-31 | €10.20 | €14.51 | x |
| 2023-12-31 | €3.56 | €14.51 | x |
| 2024-12-31 | €10.72 | €14.51 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Eckert & Ziegler Strahlen- und Medizintechnik AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.89%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.25%
- • Asset Turnover: 0.67x
- • Equity Multiplier: 1.98x
- Recent ROE (14.89%) is above the historical average (12.91%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 10.82% | 7.71% | 0.66x | 2.14x | €685.80K |
| 2014 | 7.65% | 5.32% | 0.68x | 2.11x | €-2.08 Million |
| 2015 | 10.75% | 7.67% | 0.71x | 1.97x | €748.50K |
| 2016 | 9.08% | 6.92% | 0.69x | 1.90x | €-969.00K |
| 2017 | 13.09% | 10.60% | 0.64x | 1.93x | €3.47 Million |
| 2018 | 13.15% | 9.56% | 0.74x | 1.87x | €3.87 Million |
| 2019 | 15.93% | 12.34% | 0.65x | 1.98x | €8.20 Million |
| 2020 | 15.48% | 12.99% | 0.60x | 1.98x | €8.10 Million |
| 2021 | 18.43% | 19.14% | 0.52x | 1.86x | €15.79 Million |
| 2022 | 13.81% | 13.17% | 0.53x | 1.97x | €8.07 Million |
| 2023 | 11.84% | 10.69% | 0.56x | 1.98x | €4.08 Million |
| 2024 | 14.89% | 11.25% | 0.67x | 1.98x | €10.93 Million |
Industry Comparison
This section compares Eckert & Ziegler Strahlen- und Medizintechnik AG's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $265,646,993
- Average return on equity (ROE) among peers: -84.58%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) | €233.15 Million | 10.82% | 0.94x | $610.05 Million |
| HeraMED Limited (1I4) | $-105.98K | 0.00% | 0.00x | $17.10 Million |
| Q-linea AB (publ) (3F80) | $163.19 Million | -164.65% | 0.41x | $9.23 Million |
| Guerbet SA (4G8) | $342.14 Million | 13.51% | 1.79x | $44.77 Million |
| Scandinavian Real Heart AB (Publ) (7820) | $111.29 Million | -9.42% | 0.06x | $4.77 Million |
| aap Implantate AG (AAQ1) | $54.78 Million | 26.71% | 0.17x | $9.65 Million |
| Carmat SA (CXT) | $7.48 Million | -557.76% | 3.92x | $1.62 Million |
| elexxion AG (E8X) | $-0.01 | 0.00% | 0.00x | $199.10K |
| AETHLON MEDIC.NEW DL-001 (EJU) | $15.06 Million | -79.86% | 0.16x | $446.12K |
| Gaush Meditech Ltd (F7Y) | $1.70 Billion | 10.23% | 0.68x | $29.55 Million |